Newport, United States
Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. The company markets a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.
The company is developing: Zipsor™ for the treatment of mild to moderate acute pain for which they have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S.
Xanodyne Pharmaceuticals has received a $87.78M Venture Round investment on 30 October 2009. The investors in this round include Blue Chip Venture Company, Longitude Capital, MPM Capital, EW Healthcare Partners, HealthCare Ventures, Aisling Capital, AIG Investments, Perseus-Soros Biopharmaceutical Fund, Union Spring Pharmaceuticals, Silver Point Capital, L.P.
With a focus on women's healthcare and pain management, Xanodyne Pharmaceuticals is positioned to make significant strides in the pharmaceutical industry with its innovative product pipeline and strong commercial capabilities.
Semnur Pharmaceuticals, Inc.
CoLucid Pharmaceuticals, Inc
